BBIO News and Press, BridgeBio Pharma Inc. From 06/20/23

- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height velocity (AHV), with a mean change of +3.38 cm/year from baseline - 83% of children in Cohort 5 responded to infigratinib, as defined by an increase from basel...

2023-06-15 14:04:34 ET Shares of the small-cap biotech BridgeBio Pharma (NASDAQ: BBIO) were down by 7.2% on moderate  volume as of 1:09 p.m. ET Thursday. The big loss came after JPMorgan Chase released a cautionary note on the biotech's experimental treatment of symptomatic...

2023-06-15 12:47:29 ET BridgeBio Pharma ( NASDAQ: BBIO ) shares dipped Thursday in the wake of a cautious note by JP Morgan regarding upcoming data from a pivotal study for the company's drug candidate acoramidis in the treatment of ATTR-CM. Shares of BridgeBio were down 6% at $...

2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from...

- Following treatment, the N-acetylaspartate (NAA) levels of CANaspire participants are consistent with levels seen in individuals with milder Canavan disease based on findings from the Company’s natural history study and reports in the scientific literature - Sustained reduction...

PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CAN aspire , ...

2023-05-15 06:29:07 ET Summary We put BridgeBio Pharma, Inc. in the spotlight for the first time since last summer as the company continues to have buyout speculation around it. BridgeBio also has had some positive recent trial developments and executed a needed capital raise in M...

2023-05-05 15:00:33 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-05-04 10:08:25 ET BridgeBio Pharma press release ( NASDAQ: BBIO ): Q1 GAAP EPS of -$0.92. Revenue of $1.83M (+8.3% Y/Y). For further details see: BridgeBio Pharma GAAP EPS of -$0.92, revenue of $1.83M